SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to confirm that it is involved in three poster presentations at the American Society of Clinical Oncology‘s (ASCO) Annual Meeting, in Chicago, Illinois taking place from 1 - 5 June. All three posters relate to Immutep’s lead product candidate eftilagimod alpha (“efti” or “IMP321”).
Two of the posters (TPS1050 and TPS1109), were presented on June 2, and focused on the Company’s Phase IIb AIPAC (Active Immunotherapy PAClitaxel) double blind placebo trial evaluating the efficacy of efti in patients with metastatic breast cancer.
For further information please download PDF attached:
Download this document
